Keywords
Neoplasm Staging
Urogenital Neoplasms
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To characterize the epidemiological profile, staging, and therapeutic patterns of the main gynecological, genitourinary, and anal neoplasms recorded in hospital facilities in Goiás between 2019 and 2024. Methods: An ecological, descriptive, and retrospective study using data from TABNET/DATASUS for Goiás (2019–2024). Demographic characteristics, clinical staging, and therapeutic modalities for the main gynecological and genitourinary neoplasms were analyzed using descriptive analysis of absolute and relative frequencies. Results: A total of 10,001 neoplasm cases were identified, with a predominance of prostate cancer, followed by cancers of the cervix, ovary, and uterine body. A high frequency of diagnoses at advanced stages was observed for most of the analyzed neoplasms. Cancers of the prostate, penis, anus, vagina, and vulva occurred predominantly in older patients, whereas testicular cancer primarily affected young adults. Surgery was the primary therapeutic modality, while chemotherapy predominated for prostate, cervical, and anal cancers. Conclusion: The main gynecological, genitourinary, and anal neoplasms in Goiás showed a high frequency of diagnosis at advanced stages, as well as differences in age and therapeutic profiles. These findings reinforce the importance of prevention, screening, and early diagnosis strategies, contributing to the improvement of public policies aimed at controlling these neoplasms.
References
ALLEMANI C, MATSUDA T, DI CARLO V, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. The Lancet. 2018;391(10125):1023-1075.
ARMSTRONG DK, ALVAREZ RD, BAKKUM-GAMEZ JN, et al. Ovarian cancer, version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 2021; 19(2): 191-226.
ARNOLD M, MORGAN E, RUMGAY H, et al. Current and future burden of incident cancer in Europe: a population-based study. The Lancet Regional Health – Europe, 2022; 22: 100510.
BHATLA N, AOKI D, SHARMA DN, SANKARANARAYANAN R. Cancer of the cervix uteri. Int J Gynecol Obstet. 2018;143(Suppl 2):22-36.
BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263.
CHENG L, ALBERS P, BERNEY DM, et al. Testicular cancer. Nat RevDis Primers. 2018;4:29.
COLOMBO N, LEDERMANN JA, et al. Ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(10):833-848.
CONCIN N, MATIAS-GUIU X, VERGOTE I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31(1):12-39.
CROSBIE EJ, KITSON SJ, MCALPINE JN, et al. Endometrial cancer. Nat RevDis Primers. 2022;8(1):22.
DE MAGALHÃES JP. How ageing processes influence cancer. Nat Rev Cancer. 2013;13(5):357-365.
EUROPEAN ASSOCIATION OF UROLOGY. EAU Guidelines on Penile Cancer. Arnhem: EuropeanAssociationofUrology; 2025.
EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY. ESMO Clinical Practice Guideline for Cervical Cancer. Lugano: ESMO; 2023.
GIONA S. The epidemiology of prostate cancer. In: Prostate Cancer. Brisbane: Exon Publications; 2021.
GIRDA E, RANDALL LM, CHINO F, et al. Cervical cancer treatment update: a Society of Gynecologic Oncology clinical practice statement. Gynecol Oncol. 2023;179:115-122.
HAKENBERG OW, COMPÉRAT EM, MINHAS S, et al. EAU Guidelines on Penile Cancer: 2023 update. Eur Urol. 2023.
HAMDY FC, DONOVAN JL, LANE JA, et al. 15-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2023;388(8):718-732.
HUANG Y, et al. Incidence distributions, risk factors and trends of vaginal cancer: population-based study. BMC Cancer. 2024;24(1):456.
INSTITUTO NACIONAL DE CÂNCER JOSÉ ALENCAR GOMES DA SILVA. Estimativa 2023: incidência de câncer no Brasil. Rio de Janeiro: INCA; 2022.
KNAUL FM, ARREOLA-ORNELAS H, et al. Closing the cancer divide: an equity imperative. The Lancet, 2022; 400(10357): 1198-1226.
LHEUREUX S, BRAUNSTEIN M, OZA AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280-304.
MOTTET N, et al. EAU guidelines on prostate cancer. Arnhem: European Association of Urology; 2025.
NATIONAL COMPREHENSIVE CANCER NETWORK. NCCN Clinical Practice Guidelines in Oncology. Plymouth Meeting (PA): NCCN; 2025.
NATIONAL COMPREHENSIVE CANCER NETWORK. NCCN Clinical Practice Guidelines in Oncology: Anal Carcinoma. Plymouth Meeting (PA): NCCN; 2025.
NATIONAL COMPREHENSIVE CANCER NETWORK. NCCN Clinical Practice Guidelines in Oncology: Vulvar Cancer. Plymouth Meeting (PA): NCCN; 2025.
NEAL RD, THARMANATHAN P, FRANCE B, et al. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. British Journal of Cancer, 2015; 112(Suppl 1): S92-S107.
OLIVEIRA NPD, et al. Social inequalities in the diagnosis of cervical cancer in advanced stages in Brazil. CienSaude Colet. 2024;29(6):e03872023.
PERNAR CH, EBOT EM, WILSON KM, et al. The epidemiology of prostate cancer. Cold Spring HarbPerspect Med. 2018;8(12):a030361.
RAO S, GUREN MG, KHAN K, et al. Anal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(9):1087-1100.
RAWLA P. Epidemiology of prostate cancer. World J Oncol. 2019;10(2):63-89.
RYAN NAJ, MCMAHON RF, et al. Risk factors for ovarian cancer: an umbrella review of the literature. Cancers (Basel). 2022;14(11):2708.
SEKHOACHA M, RIET K, MOTLOUNG P, et al. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules. 2022;27(17):5730.
SILVA M, MARQUES R, COSTA L. Câncer de colo de útero: barreiras preventivas no século 21. Cad Med. 2020;3(1):58-69.
SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.
TATEO V, THOMPSON ZJ, GILBERT SM, et al. Epidemiology and Risk Factors for Testicular Cancer: A Systematic Review. Eur Urol, 2025;87(4):427-441.
TEIXEIRA JC, ZEFERINO LC, VALE DB, et al. Transition from opportunistic cytological to organized HPV-based cervical cancer screening in Brazil: results from the first screening round. Sci Rep. 2024;14:22354.
WORLD HEALTH ORGANIZATION. Guide to cancer early diagnosis. Geneva: World Health Organization, 2017.
WORLD HEALTH ORGANIZATION. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention. 2nd ed. Geneva: World Health Organization; 2021.